Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors
Schellens, J. H. M., Shapiro, G., Pavlick, A. C., Tibes, R., Leijen, S., Tolaney, S. M., Diaz-Padilla, I., Ramanathan, R. K., Demuth, T., Viscusi, J., Cheng, J. D., Lam, R., Xu, Y., Oza, A. M.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor
Leijen, S., Middleton, M. R., Tresca, P., Kraeber-Bodere, F., Dieras, V., Scheulen, M. E., Tessier, J., Xu, Z. X., Shochat, E., Walz, A., Deutsch, J., Blotner, S., Lopez Valverde, V., Naegelen, V. M., Schellens, J. H. M., Eberhardt, W. E.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors
Leijen, S., Schellens, J. H., Shapiro, G., Pavlick, A. C., Tibes, R., Demuth, T., Viscusi, J., Cheng, J. D., Xu, Y., Oza, A. M.
Published in Journal of clinical oncology (20.05.2010)
Published in Journal of clinical oncology (20.05.2010)
Get full text
Journal Article
A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors
Schellens, J. H., Leijen, S., Shapiro, G. I., Pavlick, A. C., Tibes, R., O'Day, S. J., Demuth, T., Viscusi, J., Xu, Y., Oza, A. M.
Published in Journal of clinical oncology (20.05.2009)
Published in Journal of clinical oncology (20.05.2009)
Get full text
Journal Article
AML1/RUNX1 Increases During G sub(1) to S Cell Cycle Progression Independent of Cytokine-dependent Phosphorylation and Induces Cyclin D3 Gene Expression
Bernardin-Fried, F, Kummalue, T, Leijen, S, Collector, MI, Ravid, K, Friedman, AD
Published in The Journal of biological chemistry (09.04.2004)
Published in The Journal of biological chemistry (09.04.2004)
Get full text
Journal Article
Parsing observable collections
JOHN WESLEY DYER, DANIEL JOHANNES PIETER LEIJEN, HENRICUS JOHANNES MARIA MEIJER
Year of Publication 04.04.2012
Get full text
Year of Publication 04.04.2012
Patent